Alternative Mcl1-specific mimetics or inhibitors are also showing their usefulness as mono- or combined- therapeutics, as seen with S63845-mediated apoptosis of MM and NSCLC, gastric cancer (GC), PC, [74] and T-cell acute lymphoblastic leukaemia (T-ALL) cells [304] or ABT-199 and S63845 co-treatments in cervical cancer cells [335]. This evidence concerns the gene MCL1 and Miyoshi myopathy.